American Oriental Bioengineering, Inc. reported comprehensive income of $12.3 million, or $0.14 per diluted share, in the fourth quarter of 2009. This was up sharply from the $7.8 million, or $0.10 per diluted share, reported in the same quarter in 2008.

In 2009, the company increased revenue to $296.2 million from $264.6 million in 2008, an increase of 12%. Comprehensive income fell over the same time period, however, from $62.8 million, or $0.61 per diluted share, to $42.7 million, or $0.53 per diluted share, in 2009.

“We are very pleased with our 2009 performance despite the increasingly challenging economic environment worldwide and China’s rapidly changing regulatory environment. In 2009, we expanded our product portfolio, strengthened our leading brands and diversified our operations,” said Tony Liu, the CEO of American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company that manufactures and sells both prescription and over the counter products serving mostly the Chinese market. The company was founded in 1970 and maintains offices in the United States and China.

Major products of American Oriental Bioengineering, Inc. include the Jinji Series of products, Shuanghuanglian Injection Powder, the Cease Enuresis Soft Gel and Patch, YuYeQingHuo capsules and Shedanchan beiye.